FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
Subscribe To Our Newsletter & Stay Updated
